TTR and amyloidosis: Following this 'silent revolution', in 2018 the US Food and Drug Administration approved the first RNAi therapeutic, a treatment for polyneuropathy caused by transthyretin (TTR) amyloidosis, from Alnylam Pharmaceuticals18.